Alkermesの空売り状況は、投資家がAlkermesの株価下落に賭けている度合いを知ることができます。空売りデータは2週間ごとに更新されます。

Alkermes (NASDAQ:ALKS) 株価情報, 空売り情報

Alkermes

Alkermes PLC is a fully integrated biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in therapeutic areas. The company utilizes several to develop and commercialize products and, in so doing, access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies. It operates in U.S., which derives maximum revenue, Ireland and Rest of the world.

Alkermes PLC

ALKERMES PLC ORD

<p>Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.</p>
<ul>
<li>Canaccord Genuity raised <strong>Hims &amp; Hers Health, Inc.</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIMS#NYSE">HIMS</a>) price target from $24 to $28. Canaccord Genuity analyst Maria Ripps maintained a Buy rating. Hims &amp; Hers Health shares closed at $20.76 on Monday. See how other analysts view this stock.</li>
<li>Benchmark raised the price target for <strong>Charter Communications, Inc</strong>. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHTR#NASDAQ">CHTR</a>) from $440 to $450. Benchmark analyst Matthew Harrigan maintained a Buy rating. Charter Communications shares closed at $375.83 on Monday. <a href="https://www.benzinga.com/quote/CHTR/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Wells Fargo cut the price target for <strong>Celanese Corporation</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CE#NYSE">CE</a>) from $165 to $115. Wells Fargo analyst Michael Sison downgraded the stock from Overweight to Equal-Weight. Celanese shares closed at $123.50 on Monday. <a href="https://www.benzinga.com/quote/CE/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Telsey Advisory Group slashed Dollar Tree, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DLTR#NASDAQ">DLTR</a>) price target from $95 to $75. Telsey Advisory Group analyst Joseph Feldman downgraded the stock from Outperform to Market Perform. Dollar Tree shares settled at $66.81 on Monday. <a href="https://www.benzinga.com/quote/DLTR/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Susquehanna slashed <strong>Lattice Semiconductor Corporatio</strong>n (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LSCC#NASDAQ">LSCC</a>) price target from $65 to $55. Susquehanna analyst Christopher Rolland maintained a Positive rating. Lattice Semiconductor shares closed at $51.89 on Monday. <a href="https://www.benzinga.com/quote/LSCC/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Baird cut <strong>Navitas Semiconductor Corporation</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVTS#NASDAQ">NVTS</a>) price target from $7 to $5. Baird analyst Tristan Gerra maintained an Outperform rating. Navitas Semiconductor shares closed at $2.61 on Monday. <a href="https://www.benzinga.com/quote/NVTS/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Loop Capital increased the price target for <strong>Air Transport Services Group, Inc.</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATSG#NASDAQ">ATSG</a>) from $22 to $22.5. Loop Capital analyst Rick Paterson downgraded the stock from Buy to Hold. Air Transport shares settled at $22.00 on Monday. <a href="https://www.benzinga.com/quote/ATSG/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Baird cut <strong>Owens &amp; Minor, Inc</strong>. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OMI#NYSE">OMI</a>) price target from $19 to $14. Baird analyst Eric Coldwell maintained a Neutral rating. Owens &amp; Minor shares closed at $12.00 on Monday. <a href="https://www.benzinga.com/quote/OMI/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Stifel boosted the price target for <strong>Alkermes plc</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALKS#NASDAQ">ALKS</a>) from $25 to $36. Stifel analyst Paul Matteis upgraded the stock from Hold to Buy. Alkermes shares closed at $26.59 on Monday. <a href="https://www.benzinga.com/quote/ALKS/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Truist Securities boosted <strong>MasTec, Inc..</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MTZ#NYSE">MTZ</a>) price target from $133 to $173. Truist Securities analyst Jamie Cook upgraded the stock from Hold to Buy. MasTec shares closed at $132.61 on Monday. <a href="https://www.benzinga.com/quote/MTZ/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
<p><strong>Read This Next: </strong></p>
<ul>
<li><strong><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/11/41740698/top-3-health-care-stocks-youll-regret-missing-in-november">Top 3 Health Care Stocks You&#8217;ll Regret Missing In November</a></strong></li>
</ul>


News

Price Target

Pre-Market Outlook

Markets

Analyst Ratings

Trading Ideas

ALKS

ATSG

CHTR

DLTR

Hims & Hers Health, Inc. Class A Common Stock

HIMS

LSCC

NVTS

Charter Communications To Rally Around 20%? Here Are 10 Top Analyst Forecasts For Tuesday

<p>During the last three months, 9 analysts shared their evaluations of Alkermes (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALKS#NASDAQ">ALKS</a>), revealing diverse outlooks from bullish to bearish.</p>
<p>The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>Insights from analysts' 12-month price targets are revealed, presenting an average target of $38.0, a high estimate of $48.00, and a low estimate of $26.00. A 0.86% drop is evident in the current average compared to the previous average price target of $38.33. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1730808022_0.png" alt="price target chart" /></p>
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
<p>The standing of Alkermes among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Paul Matteis</td>
<td>Stifel</td>
<td>Raises</td>
<td>Buy</td>
<td>$36.00</td>
<td>$25.00</td>
</tr>
<tr>
<td>Chris Shibutani</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Buy</td>
<td>$30.00</td>
<td>$32.00</td>
</tr>
<tr>
<td>Charles Duncan</td>
<td>Cantor Fitzgerald</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$43.00</td>
<td>$48.00</td>
</tr>
<tr>
<td>Jessica Fye</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$26.00</td>
<td>$32.00</td>
</tr>
<tr>
<td>David Amsellem</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$37.00</td>
<td>$38.00</td>
</tr>
<tr>
<td>Douglas Tsao</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$37.00</td>
<td>$37.00</td>
</tr>
<tr>
<td>Douglas Tsao</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$37.00</td>
<td>$37.00</td>
</tr>
<tr>
<td>Charles Duncan</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$48.00</td>
<td>$48.00</td>
</tr>
<tr>
<td>Charles Duncan</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$48.00</td>
<td>$48.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Alkermes. This offers insight into analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Alkermes compared to the broader market.</li>
<li><strong>Price Targets:</strong> Gaining insights, analysts provide estimates for the future value of Alkermes's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Alkermes's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/ALKS/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Alkermes analyst ratings.</strong></a></p>
<h2>About Alkermes</h2>
<p>Alkermes PLC is a fully integrated biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in therapeutic areas. The company utilizes several to develop and commercialize products and, in so doing, access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies. It operates in U.S., which derives maximum revenue, Ireland and Rest of the world.</p>
<h3>A Deep Dive into Alkermes's Financials</h3>
<p><strong>Market Capitalization:</strong> With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.</p>
<p><strong>Revenue Growth:</strong> Alkermes's revenue growth over a period of 3 months has faced challenges. As of 30 September, 2024, the company experienced a revenue decline of approximately <strong>-0.73%</strong>. This indicates a decrease in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.</p>
<p><strong>Net Margin:</strong> Alkermes's net margin excels beyond industry benchmarks, reaching <strong>24.43%</strong>. This signifies efficient cost management and strong financial health.</p>
<p><strong>Return on Equity (ROE):</strong> Alkermes's ROE excels beyond industry benchmarks, reaching <strong>7.17%</strong>. This signifies robust financial management and efficient use of shareholder equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> Alkermes's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>4.24%</strong> ROA, the company effectively utilizes its assets for optimal returns.</p>
<p><strong>Debt Management:</strong> Alkermes's debt-to-equity ratio is below the industry average. With a ratio of <b>0.28</b>, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.</p>
<h2>The Basics of Analyst Ratings</h2>
<p>Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.</p>
<p>In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


A Glimpse Into The Expert Outlook On Alkermes Through 9 Analysts

<p>Stifel  analyst Paul Matteis   upgrades Alkermes (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALKS#NASDAQ">ALKS</a>) from Hold to Buy and raises the price target from $25 to $36.</p>


Upgrades

Stifel Upgrades Alkermes to Buy, Raises Price Target to $36

<p>Goldman Sachs  analyst Chris Shibutani   maintains Alkermes (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALKS#NASDAQ">ALKS</a>) with a Buy and lowers the price target from $32 to $30.</p>


Goldman Sachs Maintains Buy on Alkermes, Lowers Price Target to $30

<p>Cantor Fitzgerald  analyst Charles Duncan   maintains Alkermes (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALKS#NASDAQ">ALKS</a>) with a Overweight and lowers the price target from $48 to $43.</p>


Cantor Fitzgerald Maintains Overweight on Alkermes, Lowers Price Target to $43

<p>JP Morgan  analyst Jessica Fye   maintains Alkermes (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALKS#NASDAQ">ALKS</a>) with a Neutral and lowers the price target from $32 to $26.</p>


JP Morgan Maintains Neutral on Alkermes, Lowers Price Target to $26

<p>Piper Sandler  analyst David Amsellem   reiterates Alkermes (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALKS#NASDAQ">ALKS</a>) with a Overweight and lowers the price target from $38 to $37.</p>


Reiteration

Piper Sandler Reiterates Overweight on Alkermes, Lowers Price Target to $37

<p>HC Wainwright &amp; Co.  analyst Douglas Tsao   reiterates Alkermes (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALKS#NASDAQ">ALKS</a>) with a Neutral and maintains $37 price target.</p>


HC Wainwright & Co. Reiterates Neutral on Alkermes, Maintains $37 Price Target

Earnings

Alkermes Q3 2024 GAAP EPS $0.56 Misses $0.59 Estimate, Sales $378.143M Miss $380.760M Estimate

<p>Alkermes (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALKS#NASDAQ">ALKS</a>) is gearing up to announce its quarterly earnings on Thursday, 2024-10-24. Here's a quick overview of what investors should know before the release.</p>
<p>Analysts are estimating that Alkermes will report an <strong>earnings per share</strong> (EPS) of $0.74.</p>
<p>Anticipation surrounds Alkermes's announcement, with investors hoping to hear about both surpassing estimates and receiving positive guidance for the next quarter.</p>
<p>New investors should understand that while earnings performance is important, market reactions are often driven by guidance.</p>
<h3>Overview of Past Earnings</h3>
<p>The company's EPS beat by $0.02 in the last quarter, leading to a 5.77% increase in the share price on the following day.</p>
<p>Here's a look at Alkermes's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
<th><strong>Q3 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.70</td>
<td>0.58</td>
<td>0.51</td>
<td>0.43</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.72</td>
<td>0.44</td>
<td>0.48</td>
<td>0.64</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>6.0%</td>
<td>-1.0%</td>
<td>-1.0%</td>
<td>5.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1729702870_0.png" alt="eps graph" /></p>
<h3>Performance of Alkermes Shares</h3>
<p>Shares of Alkermes were trading at $28.1 as of October 22. Over the last 52-week period, shares are up 22.14%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. </p>
<h3>Analysts' Perspectives on Alkermes</h3>
<p>Understanding market sentiments and expectations within the industry is crucial for investors. This analysis delves into the latest insights on Alkermes.</p>
<p>Analysts have provided Alkermes with 7 ratings, resulting in a consensus rating of Outperform. The average one-year price target stands at $41.14, suggesting a potential 46.41% upside.</p>
<h3>Analyzing Analyst Ratings Among Peers</h3>
<p>The following analysis focuses on the analyst ratings and average 1-year price targets of Ultragenyx Pharmaceutical, TG Therapeutics and Blueprint Medicines, three prominent industry players, providing insights into their relative performance expectations and market positioning.</p>
<ul>
<li>The consensus outlook from analysts is an Outperform trajectory for Ultragenyx Pharmaceutical, with an average 1-year price target of $91.64, indicating a potential 226.12% upside.</li>
<li>The prevailing sentiment among analysts is an Buy trajectory for TG Therapeutics, with an average 1-year price target of $38.0, implying a potential 35.23% upside.</li>
<li>Analysts currently favor an Buy trajectory for Blueprint Medicines, with an average 1-year price target of $126.6, suggesting a potential 350.53% upside.</li>
</ul>
<h3>Peer Metrics Summary</h3>
<p>Within the peer analysis summary, vital metrics for Ultragenyx Pharmaceutical, TG Therapeutics and Blueprint Medicines are presented, shedding light on their respective standings within the industry and offering valuable insights into their market positions and comparative performance.</p>
<p>
<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alkermes</td>
<td>Outperform</td>
<td>-35.35%</td>
<td>$337.66M</td>
<td>7.20%</td>
</tr>
<tr>
<td>Ultragenyx Pharmaceutical</td>
<td>Outperform</td>
<td>35.75%</td>
<td>$125.75M</td>
<td>-45.96%</td>
</tr>
<tr>
<td>TG Therapeutics</td>
<td>Buy</td>
<td>357.05%</td>
<td>$65.16M</td>
<td>4.07%</td>
</tr>
<tr>
<td>Blueprint Medicines</td>
<td>Buy</td>
<td>139.98%</td>
<td>$130.56M</td>
<td>-15.85%</td>
</tr>
</tbody>
</table>
</p>
<p>Key Takeaway:</p>
<p>Alkermes ranks at the bottom for Revenue Growth and Gross Profit, while it is in the middle for Return on Equity.</p>
<h3>About Alkermes</h3>
<p>Alkermes PLC is a fully integrated biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in therapeutic areas. The company utilizes several to develop and commercialize products and, in so doing, access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies. It operates in U.S., which derives maximum revenue, Ireland and Rest of the world.</p>
<h3>Breaking Down Alkermes's Financial Performance</h3>
<p><strong>Market Capitalization:</strong> With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.</p>
<p><strong>Negative Revenue Trend:</strong> Examining Alkermes's financials over 3 months reveals challenges. As of 30 June, 2024, the company experienced a decline of approximately <strong>-35.35%</strong> in revenue growth, reflecting a decrease in top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.</p>
<p><strong>Net Margin:</strong> Alkermes's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>22.89%</strong> net margin, the company effectively manages costs and achieves strong profitability.</p>
<p><strong>Return on Equity (ROE):</strong> The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of <strong>7.2%,</strong> the company showcases effective utilization of equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> Alkermes's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of <strong>4.22%,</strong> the company showcases efficient use of assets and strong financial health.</p>
<p><strong>Debt Management:</strong> Alkermes's debt-to-equity ratio is below the industry average at <strong>0.29</strong>, reflecting a lower dependency on debt financing and a more conservative financial approach.</p>
<p><a href="https://www.benzinga.com/quote/ALKS/earnings"><strong>To track all earnings releases for Alkermes visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


Alkermes's Earnings: A Preview

<p>Alkermes (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALKS#NASDAQ">ALKS</a>) has been analyzed by 7 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.</p>
<p>The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $40.29, a high estimate of $48.00, and a low estimate of $31.00. This current average has increased by 1.08% from the previous average price target of $39.86. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1728590446_0.png" alt="price target chart" /></p>
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
<p>A comprehensive examination of how financial experts perceive Alkermes is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Charles Duncan</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$48.00</td>
<td>$48.00</td>
</tr>
<tr>
<td>Charles Duncan</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$48.00</td>
<td>$48.00</td>
</tr>
<tr>
<td>Charles Duncan</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$48.00</td>
<td>$48.00</td>
</tr>
<tr>
<td>Jessica Fye</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Neutral</td>
<td>$32.00</td>
<td>$31.00</td>
</tr>
<tr>
<td>Joel Beatty</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$38.00</td>
<td>$37.00</td>
</tr>
<tr>
<td>Douglas Tsao</td>
<td>HC Wainwright &amp; Co.</td>
<td>Raises</td>
<td>Neutral</td>
<td>$37.00</td>
<td>$35.00</td>
</tr>
<tr>
<td>Jessica Fye</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$31.00</td>
<td>$32.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Alkermes. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Alkermes compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts provide insights into price targets, offering estimates for the future value of Alkermes's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>Capture valuable insights into Alkermes's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/ALKS/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Alkermes analyst ratings.</strong></a></p>
<h2>Discovering Alkermes: A Closer Look</h2>
<p>Alkermes PLC is a fully integrated biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in therapeutic areas. The company utilizes several to develop and commercialize products and, in so doing, access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies. It operates in U.S., which derives maximum revenue, Ireland and Rest of the world.</p>
<h3>Alkermes's Economic Impact: An Analysis</h3>
<p><strong>Market Capitalization Analysis:</strong> With a profound presence, the company's market capitalization is above industry averages. This reflects substantial size and strong market recognition.</p>
<p><strong>Revenue Challenges:</strong> Alkermes's revenue growth over 3 months faced difficulties. As of 30 June, 2024, the company experienced a decline of approximately <strong>-35.35%</strong>. This indicates a decrease in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.</p>
<p><strong>Net Margin:</strong> Alkermes's net margin excels beyond industry benchmarks, reaching <strong>22.89%</strong>. This signifies efficient cost management and strong financial health.</p>
<p><strong>Return on Equity (ROE):</strong> Alkermes's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of <strong>7.2%,</strong> the company showcases efficient use of equity capital and strong financial health.</p>
<p><strong>Return on Assets (ROA):</strong> Alkermes's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of <strong>4.22%,</strong> the company showcases efficient use of assets and strong financial health.</p>
<p><strong>Debt Management:</strong> The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at <strong>0.29</strong>.</p>
<h2>The Basics of Analyst Ratings</h2>
<p>Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.</p>
<p>Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Decoding 7 Analyst Evaluations For Alkermes

<p>Cantor Fitzgerald  analyst Charles Duncan   reiterates Alkermes (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALKS#NASDAQ">ALKS</a>) with a Overweight and maintains $48 price target.</p>


Cantor Fitzgerald Reiterates Overweight on Alkermes, Maintains $48 Price Target

Biotech

Health Care

General

Alkermes Announced Plans To Present Clinical Data From Its Phase 1B Study Of ALKS 2680 In Patients With Narcolepsy Type 2 And Idiopathic Hypersomnia At The European Sleep Research Society Congress, Sleep Europe 2024

<p>Across the recent three months, 6 analysts have shared their insights on Alkermes (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALKS#NASDAQ">ALKS</a>), expressing a variety of opinions spanning from bullish to bearish.</p>
<p>The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>In the assessment of 12-month price targets, analysts unveil insights for Alkermes, presenting an average target of $39.0, a high estimate of $48.00, and a low estimate of $31.00. Surpassing the previous average price target of $38.50, the current average has increased by 1.3%.</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1726520475_0.png" alt="price target chart" /></p>
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
<p>A clear picture of Alkermes's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Charles Duncan</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$48.00</td>
<td>$48.00</td>
</tr>
<tr>
<td>Charles Duncan</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$48.00</td>
<td>$48.00</td>
</tr>
<tr>
<td>Jessica Fye</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Neutral</td>
<td>$32.00</td>
<td>$31.00</td>
</tr>
<tr>
<td>Joel Beatty</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$38.00</td>
<td>$37.00</td>
</tr>
<tr>
<td>Douglas Tsao</td>
<td>HC Wainwright &amp; Co.</td>
<td>Raises</td>
<td>Neutral</td>
<td>$37.00</td>
<td>$35.00</td>
</tr>
<tr>
<td>Jessica Fye</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$31.00</td>
<td>$32.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Alkermes. This offers insight into analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Alkermes compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts predict movements in price targets, offering estimates for Alkermes's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
<p>Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Alkermes's market standing. Stay informed and make data-driven decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/ALKS/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Alkermes analyst ratings.</strong></a></p>
<h2>About Alkermes</h2>
<p>Alkermes PLC is a fully integrated biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in therapeutic areas. The company utilizes several to develop and commercialize products and, in so doing, access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies. It operates in U.S., which derives maximum revenue, Ireland and Rest of the world.</p>
<h3>Understanding the Numbers: Alkermes's Finances</h3>
<p><strong>Market Capitalization:</strong> Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.</p>
<p><strong>Negative Revenue Trend:</strong> Examining Alkermes's financials over 3 months reveals challenges. As of 30 June, 2024, the company experienced a decline of approximately <strong>-35.35%</strong> in revenue growth, reflecting a decrease in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.</p>
<p><strong>Net Margin:</strong> The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of <strong>22.89%,</strong> the company showcases strong profitability and effective cost control.</p>
<p><strong>Return on Equity (ROE):</strong> Alkermes's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>7.2%</strong> ROE, the company effectively utilizes shareholder equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> Alkermes's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of <strong>4.22%,</strong> the company showcases efficient use of assets and strong financial health.</p>
<p><strong>Debt Management:</strong> The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at <strong>0.29</strong>.</p>
<h2>Analyst Ratings: Simplified</h2>
<p>Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.</p>
<p>Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Alkermes Stock: A Deep Dive Into Analyst Perspectives (6 Ratings)

Alkermes Announces Initiation Of Vibrance-2 Phase 2 Study Evaluating ALKS 2680 For Treatment Of Narcolepsy Type 2

Guidance

Alkami Sees Q3 Total Revenue $83.8M-$85.3M vs $84.78M Est., Sees FY24 Total Revenue $330.5M-$333.5M vs $331.67M Est.

<p>JP Morgan  analyst Jessica Fye   maintains Alkermes (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALKS#NASDAQ">ALKS</a>) with a Neutral and raises the price target from $31 to $32.</p>


JP Morgan Maintains Neutral on Alkermes, Raises Price Target to $32

Analyst Douglas Tsao from H.C. Wainwright reiterated a Hold rating on Alkermes (ALKS – Research Report) and keeping the price target at $37.00. Dou...

Alkermes: Navigating Revenue Shifts and Investing in Orexin-2 Agonist Amidst Neutral Profit Outlook

BofA analyst Jason Gerberry lowered the firm's price target on Alkermes (ALKS) to $28 from $29 and keeps a Neutral rating on the shares. The compan...

Alkermes price target lowered to $28 from $29 at BofA

In a report released today, Jason Gerberry from Bank of America Securities maintained a Hold rating on Alkermes (ALKS – Research Report). The compa...

Bank of America Securities Sticks to Its Hold Rating for Alkermes (ALKS)

Robert W. Baird analyst Joel Beatty maintained a Buy rating on Alkermes (ALKS – Research Report) yesterday and set a price target of $38.00. Joel B...

Alkermes: Strong Buy Rating Amidst Short-term Challenges and Long-term Growth Potential

Leerink Partners analyst Marc Goodman has maintained their neutral stance on ALKS stock, giving a Hold rating today. Marc Goodman has given his Hol...

Alkermes: Balancing Near-Term Challenges with Long-Term Orexin Market Potential Justifies Hold Rating

J.P. Morgan analyst Jessica Fye maintained a Hold rating on Alkermes (ALKS – Research Report) yesterday and set a price target of $26.00. The compa...

Alkermes (ALKS) Gets a Hold from J.P. Morgan

Mizuho Securities analyst Uy Ear has maintained their bullish stance on ALKS stock, giving a Buy rating on October 25. Uy Ear has given his Buy rat...

Alkermes Inc.: Strong Q3 Performance and Strategic Growth Drive Buy Rating

Stifel Nicolaus analyst Paul Matteis maintained a Hold rating on Alkermes (ALKS – Research Report) on October 25 and set a price target of $25.00. ...

Alkermes (ALKS) Gets a Hold from Stifel Nicolaus

Stifel analyst Paul Matteis upgraded Alkermes (ALKS) to Buy from Hold with a price target of $36, up from $25. Published first on TheFly – the ulti...

Alkermes upgraded to Buy from Hold at Stifel

Alkermes raised to buy by Stifel on increased confidence for ALKS2680

Press Releases

Alkermes to Report Second Quarter Financial Results on July 24, 2024

Alkermes plc Reports Second Quarter 2024 Financial Results

Alkermes Announces Initiation of Vibrance-2 Phase 2 Study Evaluating ALKS 2680 for the Treatment of Narcolepsy Type 2

Alkermes to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference

Alkermes Announces Launch of 7th Annual Alkermes Pathways Research Awards® Program

Alkermes to Participate in the TD Cowen 4th Annual Novel Mechanisms in Neuropsychiatry Conference

Alkermes to Present Positive Clinical Data From Phase 1b Study of ALKS 2680 in Patients With Narcolepsy Type 2 and Idiopathic Hypersomnia at Sleep Europe 2024

Comments

Alkermes

空売り

Alkermes (NASDAQ:ALKS) 株価情報, 空売り情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル